Chemotherapy Naive Articles

A remarkable therapeutic efficacy has been demonstrated with 225Ac-prostate-specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients.

CHICAGO, IL USA (UroToday.com) - Presented by Charles J. Ryan,¹ Anil Londhe,² Arturo Molina,³ Matthew R. Smith,⁴ Johann S. de Bono,⁵ Peter F.A. Mulders,⁶ Dana Rathkopf,⁷ Fred Saad,⁸ Christopher J. Logothetis,⁹ Karim Fizazi,¹⁰ Howard I. Scher,⁷ Eric J. Small,¹ Shannon Matheny,³ Thian Kheoh,³ and Thomas W. Griffin³ at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

CHICAGO, IL USA (UroToday.com) - Presented by Charles J. Ryan, MD¹on behalf of Anil Londhe,² Arturo Molina,³ Matthew R. Smith,⁴ Johann S. de Bono,⁵ Peter F.A. Mulders,⁶ Dana Rathkopf,⁷ Fred Saad,⁸ Christopher J. Logothetis,⁹ Karim Fizazi,¹⁰ Howard I. Scher,⁷ Eric J. Small,¹ Shannon Matheny,³ Thian Kheoh,³ and Thomas W. Griffin³ at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

CHICAGO, IL USA (UroToday.com) - Presented by Charles J. Ryan,¹ Anil Londhe,² Arturo Molina,³ Matthew R. Smith,⁴ Johann S. de Bono,⁵ Peter F.A. Mulders,⁶ Dana Rathkopf,⁷ Fred Saad,⁸ Christopher J. Logothetis,⁹ Karim Fizazi,¹⁰ Howard I. Scher,⁷ Eric J. Small,¹ Shannon Matheny,³ Thian Kheoh,³ and Thomas W. Griffin³ at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

Prostate cancer is the most common malignancy in male patients. The second-generation taxanes, cabazitaxel, is a therapeutic option with an overall survival advantage for patients with metastatic castration-resistant prostate cancer.

Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and bone-targeted therapy (BTT) has become part of the overall treatment strategy.

Investigation of outcomes for concomitant BTT in a post hoc analysis of the COU-AA-302 trial, which demonstrated an overall clinical benefit of abiraterone acetate (AA) plus prednisone over placebo plus prednisone in asymptomatic or mildly symptomatic chemotherapy-naïve mCRPC patients.